| Accuracy of algorithms to identify pulmonary arterial hypertension in administrative data: a systematic review KR Gillmeyer, MM Lee, AP Link, ES Klings, ST Rinne, RS Wiener Chest 155 (4), 680-688, 2019 | 30 | 2019 |
| Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data KR Gillmeyer, ER Nunez, ST Rinne, SX Qian, ES Klings, RS Wiener Chest 159 (5), 1986-1994, 2021 | 13 | 2021 |
| Rationale and Design of the Awake Prone Position for Early Hypoxemia in COVID-19 (APPEX-19) Study Protocol MA Garcia, GL Rampon, G Doros, S Jia, N Jagan, K Gillmeyer, A Berical, ... Annals of the American Thoracic Society, 2021 | 8* | 2021 |
| Factors associated with potentially inappropriate phosphodiesterase-5 inhibitor use for pulmonary hypertension in the United States, 2006 to 2015 KR Gillmeyer, ST Rinne, ME Glickman, KM Lee, Q Shao, SX Qian, ... Circulation: Cardiovascular Quality and Outcomes 13 (5), e005993, 2020 | 8 | 2020 |
| Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease KR Gillmeyer, DR Miller, ME Glickman, SX Qian, ES Klings, BA Maron, ... Pulmonary circulation 11 (2), 20458940211001714, 2021 | 7 | 2021 |
| How Closely Do Clinical Trial Participants Resemble “Real-World” Patients with Groups 2 and 3 Pulmonary Hypertension? A Structured Review KR Gillmeyer, ST Rinne, AJ Walkey, SX Qian, RS Wiener Annals of the American Thoracic Society 17 (6), 779-783, 2020 | 6 | 2020 |
| Multisystem healthcare use among US veterans with pulmonary hypertension KR Gillmeyer, KM Lee, Q Shao, DR Miller, BA Maron, ES Klings, ST Rinne, ... Annals of the American Thoracic Society 16 (8), 1072-1074, 2019 | 2 | 2019 |
| Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis JK Lui, NA Bosch, KR Gillmeyer, CC Reardon American Journal of Respiratory and Critical Care Medicine 202 (6), 878-880, 2020 | 1 | 2020 |
| Outpatient Evaluation and Follow-Up of Veterans with Group 3 Pulmonary Hypertension Treated with Phosphodiesterase-5-Inhibitors SW Johnson, KR Gillmeyer, S Qian, ES Klings, R Wiener TP82. TP082 LET IT BE-CLINICAL ADVANCES IN PULMONARY VASCULAR DISEASE: PAH …, 2021 | | 2021 |
| Baseline Assessment and Follow Up of Veterans with Groups 2 and 3 Pulmonary Hypertension Treated with Vasodilator Therapy: A Qualitative Study KR Gillmeyer, SW Johnson, RE Bolton, MB Mccullough, R Wiener TP82. TP082 LET IT BE-CLINICAL ADVANCES IN PULMONARY VASCULAR DISEASE: PAH …, 2021 | | 2021 |
| Outcomes of Pulmonary Vasodilator Use in a National Cohort of Veterans with Pulmonary Hypertension Associated with Left Heart Disease and Lung Disease KR Gillmeyer, DR Miller, ST Rinne, SX Qian, JT Hanlon, ME Glickman, ... A56. LEFT HEART DISEASE, METABOLISM AND OBESITY IN PULMONARY HYPERTENSION …, 2020 | | 2020 |
| Pulmonary Arterial Hypertension Too Complex for Physicians, Too Complex for ICD Diagnosis Codes Response KR Gillmeyer, MM Lee, AP Link, ES Klings, ST Rinne, RS Wiener CHEST 155 (5), 1077-1078, 2019 | | 2019 |
| Factors Associated with Guideline-Discordant Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension Among US Veterans, 2006-2015 KR Gillmeyer, KM Lee, Q Shao, ME Glickman, JT Hanlon, DR Miller, ... A105. GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH, A2506-A2506, 2019 | | 2019 |
| Impact of Multi-System Healthcare Use on Pulmonary Hypertension Management Among US Veterans KR Gillmeyer, K Lee, Q Shao, M Glickman, J Hanlon, D Miller, S Rinne, ... C70. WHO'S NEXT? NEW INSIGHTS INTO ATYPICAL WHO GROUP 1 AND GROUP 2-5 PH …, 2018 | | 2018 |
| An Unusual Cause Of Cardiac Arrest In A Paraplegic Patient R Strykowski, K Gillmeyer, ES Klings B56. CRITICAL CARE CASE REPORTS: ICU TOXICOLOGY, A3795-A3795, 2017 | | 2017 |
| Organizational Structures and Processes Associated with Low-Value Care of Ph Care Among Veterans K Gillmeyer, M McCullough, A Solch, R Bolton, R Wiener 2020 Virtual Annual Research Meeting, 0 | | |
Mark GlickmanHarvard UniversityVerifierad e-postadress på fas.harvard.edu
